Clinical experience with antivirals

  • M. Eisenberg
  • T. C. Merigan


Nearly a half century has passed since the modern antimicrobial era began with the introduction of sulphanilamide in 1936. Since that time a vast array of antibiotic agents have been discovered which have improved our therapeutic armamenterium against microbes. Yet, it has only been in the past decade that real progress has been made in the development of specific antiviral therapy.


Herpes Simplex Herpes Zoster Genital Herpes Herpes Simplex Encephalitis Bone Marrow Transplant Recipient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. ARVIN, A.M., FELDMAN, S. & MERIGAN, T.C. (1978). Human leukocyte interferon in the treatment of varicella in children with cancer: a preliminary controlled trial. Antimicrob. Agents Chemother., 13, 605–607.Google Scholar
  2. ARVIN, A.M., KUSHNER, J.H., FELDMAN, S., BAEHNER, R.L., HAMMOND, D. & MERIGAN, T.C. (1982). Human leukocyte interferon for the treatment of varicella in children with cancer. N. Engl. J. Med., 306, 761–765.Google Scholar
  3. ARVIN, A.M., YEAGER, A.S. & MERIGAN, T.C. (1976). Effect of leukocyte interferon on urinary excretion of cytomegalovirus by infants. J. Infect. Dis., 133 (Suppl.), A205–A210.Google Scholar
  4. BALFOUR, H.H., Jr, BEAN, B., LASKIN, O.L., AMBINDER, R.F., MEYERS, J.D., WADE, J.C. & 5 OTHERS. (1983). Acyclovir halts progression of herpes zoster in immunocompromised patients. N. Engl. J. Med., 308, 1448–1453.Google Scholar
  5. BALFOUR, H.H., Jr, BEAN, B., MITCHELL, C.D., SACHS, G.W., BOEN, J.R. & EDELMAN, C.K. (1982). Acyclovir in immunocompromised patients with cytomegalovirus disease: a controlled trial at one institution. Am. J. Med., 73 (Suppl. 1A), 241–248.Google Scholar
  6. BASSENDINE, M.F., CHADWICK, R.G., SALMERON, J., SHIPTON, V., THOMAS, H.C. & SHERLOCK, S. (1981). Adenine arabinoside therapy in HBsAg-positive chronic liver disease: a controlled study. Gastroenterology, 80, 1016–1022.Google Scholar
  7. CARMINE, A.A., BROGDEN, R.N., HEEL, R.C., STEIGHT, T.M. & AVERY, G.S. (1982). Trifluridine: a review of its antiviral activity and therapeutic use in the topical treatment of viral eye infections. Drugs, 23, 329–353.Google Scholar
  8. CHADWICK, R., JAIN, S., CHOEN, J., SCOTT, G., THOMAS, H., SHERLOCK, S. (1980). Levamisole therapy for HBsAg-positive chronic liver disease. Scan. J. Gastroent., 15, 973–978.CrossRefGoogle Scholar
  9. CHEESEMAN, S.H., RUBIN, R.H., STEWART, J.A., TOLKOFF-RUBIN, N.E., COSIMI, A.B., CANTELL, K. 6 OTHERS. (1979). Controlled clinical trial of prophylactic human-leukocyte interferon in renal transplantation. N. Engl. J. Med., 300, 1345–1349.Google Scholar
  10. CHOU, S.W., DYLEWSKI, J.S., GAYNON, M.W., EGBERT, P.R. & MERIGAN T.C. (1984). Alpha-interferon administration in cytomegalovirus retinitis. Antimicrob. Agents Chemother., 25, 25–28.Google Scholar
  11. CHOU, S. W., GALLAGHER, J.G. & MERIGAN, T.C. (1981). Controlled clinical trial of intravenous acyclovir in heart-transplant patients with mucocutaneous herpes simplex infections. Lancet, i, 1392–1394.Google Scholar
  12. CONDIE, R.M. & O’REILLY, R.J. (1984). Prevention of cytomegalovirus infection by prophylaxis with an intravenous, hyperimmune, native unmodified cytomegalovirus globulin. Am. J. Med., 76, (Suppl. 3A), 134–141.Google Scholar
  13. COREY, L., NAHMIAS, A.J., GUINAN, M.E., BENEDETTI, J.K., CRITCHLOW, C.W. & HOLMES, K.K. (1982). A trial of topical acyclovir in genital herpes simplex virus infections. N. Engl. J. Med., 306, 1313–1319.Google Scholar
  14. DECLERCQ, E., DESCAMPS, E.J., DESOMER, P., BARR, P.M., JONES, A.S. & WALKER, R.T. (1979). (E)-5-(2-bromovinyl)-2′-deoxyuridine: a potent and selective anti-herpes agent. Proc. natn. Acad. Sci. U.S.A., 76, 2947–2951.Google Scholar
  15. DE KONING, E.W.J., VAN BIJSTERVELD, O.P. & CANTELL, K. (1982). Combination therapy for dendritic keratitis with human leucocyte interferon with trifluorothymidine. Br. J. Ophthalmol., 66, 509–512.Google Scholar
  16. ELLIS-PEGLER, R., SUTHERLAND, D.C. & DOUGLAS, R. (1979). Transfer factor and hepatitis B: a double blind study. Clin. Exp. Immunol., 36, 221–226.Google Scholar
  17. GERSHON, A., STEINBERG, S. & BRUNELL, P. (1974). Zoster immune globulin: a further assessment. N. Engl. J. Med., 290, 243–245.Google Scholar
  18. GLUCKMAN, E., LOTSBERG, J., DEVERGIE, A., ZHAO, X.M., MELO, R., GOMEZ-MORALES, M., NEBOUT, T., MAZERON, M.C. & PEROL, Y. (1983). Prophylaxis of herpes infections after bone-marrow transplantation by oral acyclovir. Lancet, ii, 706–708.Google Scholar
  19. GREENBERG, H.B., POLLARD, R.B., LUTWICK, L.I., GREGORY, P.B., ROBINSON, W.S., MERIGAN, T.C. (1976). Effects of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N. Engl. J. Med., 295, 517.PubMedCrossRefGoogle Scholar
  20. GREGORY, P.B. (1984). Antivirals in chronic hepatitis B — problems of small clinical trials. Gastroenterology, 86, 201–203.PubMedGoogle Scholar
  21. HAGLUND, S., LUNDQUIST, P.G., CANTELL, K. & STRANDER, H. (1981). Interferon therapy in juvenile laryngeal papillomatosis. Arch. Otolyrngol., 107, 327–332.Google Scholar
  22. HANN, I.M., PRENTICE, H.G., BLACKLOCK, H.A., ROSS, M.G.R., BRIGDEN, D., ROSLING, A.E. 4 OTHERS. (1983). Acyclovir prophylaxis against herpes virus infections in severely immunocompromised patients: randomized double blind trial. Br. Med. J., 287, 384–388.CrossRefGoogle Scholar
  23. HANTO, D.W., FRIZZERA, G., GAJL-PECZALSKA, K.J., SAKAMOTO, K., PURTILO, D.T., BALFOUR, H.H., SIMMONS, R.L. & NAJARIAN, J.S. (1982). Epstein-Barr virus-induced B-cell lymphoma after renal transplantation. N. Engl. J. Med., 306, 913–918.Google Scholar
  24. HIRSCH, M.S., SCHOOLEY, R.T., COSIMI, A.B., RUSSEL, P.S., DELMONICO, F.L., TOLKOFF-RUBIN, N.E. 5 OTHERS. (1983). Effects of interferon-alpha on cytomegalovirus reaction syndromes in renal-transplant recipients. N. Engl. J. Med., 308, 1489–1493.Google Scholar
  25. HOOFNAGLE, J.H., DUSHEIKO, G.M., SCHAFER, D.F., JONES, E.A., MICETICH, K.C., YOUNG, R.C. & COSTA, J. (1982a). Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann. intern. Med., 96, 447.Google Scholar
  26. HOOFNAGLE, J.H., HANSON, R.G. & MINUK, G.Y., PAPPAS, S.C., SCHAFER, D.F., DUSHELKO, G.M., STRAUSS, S.E., POPPER, H. & JONES, E.A. (1984). Randomized controlled trial of adenine arabinoside monophosphate for chronic type B hepatitis. Gastroenterology, 86, 150–157.Google Scholar
  27. HOOFNAGLE, J.H., MINUK, G.Y., DUSHEIKO, G.M., SHAFER, D.F., JOHNSON, R., STRAUS, S., JONES, E.A., GERIN, J.L. & ISHAK, K. (1982b). Adenine arabinoside 5′monophosphate treatment of chronic type B hepatitis. Hepatology, 2, 784–788.Google Scholar
  28. JAIN, S., THOMAS, H., OXFORD, J. & SHERLOCK, S. (1978). Trial of ribavirin for the treatment of HBsAg positive chronic liver disease. J. Antimicro. Chemother., 4, 367–373.Google Scholar
  29. JUDELSOHN, R.G., MEYERS, J.D., ELLIS, R.J., THOMAS, E.K. (1974). Efficacy of zoster immune globulin. Pediatrics, 53, 476–480.PubMedGoogle Scholar
  30. KAUFMAN, H.E., MARTOLA, E., DOHLMAN, L. (1962). Use of 5-iodo-2′- deoxyuridine (IDU) in the treatment of herpes simplex keratitis. Arch. Ophthalmol., 68, 235–239.PubMedCrossRefGoogle Scholar
  31. KIM, K.S., SAPIENZA, V.J., CARP, R.I. (1980). Antiviral activity of arildone on deoxyribonucleic acid and ribonucleic acid viruses. Antimicrob. Agents Chemother., 18, 276–280.PubMedPubMedCentralCrossRefGoogle Scholar
  32. KRAMER, P., TANKATE, F.W.J., BINJNEN, A.B., JEEKEL, J. & WEIMAR, W. (1984). Recombinant leucocyte interferon A induces steroid-resistant acute vascular rejection episodes in renal transplant recipients. Lancet, i, 989–990.Google Scholar
  33. LA LAU, C., OOSTERHIUS, J.A., VERSTEEG, J., VAN RIJ, C., RENARDEL DE LAVALETTE, J.G., CRAANDIJK, A., LAMERS, W.R. & MIERLOBENSTEYN, T. (1982). Multicenter trial of acyclovir and trifluorothymidine in herpetic keratitis. Am. J. Med., 73 (Suppl. 1A), 305–306.Google Scholar
  34. LAM, K.C., LAI, C.L., NG, R.P., et al. (1981). Deleterious effect of prednisolone in HBsAg-positive chronic active hepatitis. N. Engl. J. Med., 304, 380.PubMedCrossRefGoogle Scholar
  35. MARKER, S.C., HOWARD, R.J., GROTH, K.E., MASTRI. A.R., SIMMONS, R.L. & BALFOUR, H.H., Jr (1980). A trial of vidarabine for cytomegalovirus infection in renal transplant patients. Arch. intern. Med., 140, 1441–1444.Google Scholar
  36. MERIGAN, T.C., RAND, K.H., POLLARD, R.B., ABDALLAH, P.S., JORDAN, G.W. & FRIED, R.P. (1978). Human leukocyte interferon for the treatment of herpes zostet in patients with cancer. N. Engl. J. Med., 298, 981–987.Google Scholar
  37. MEYERS, J.D., McGUFFIN, R.W., BRYSON, Y.J., CANTELL, K. & THOMAS, E.D. (1982b). Treatment of cytomegalovirus pneumonia after marrow transplant with combined vidarabine and human leukocyte interferon. J. Infect. Dis., 146, 80–84.Google Scholar
  38. MEYERS, J.D., McGUFFIN, R.W., NEIMAN, P.E., SINGER, J.W. & THOMAS, E.D. (1980). Toxicity and efficacy of human leukocyte interferon for the treatment of cytomegalovirus pneumonia after marrow transplantation. J. Infect. Dis., 141, 555–562.Google Scholar
  39. MEYERS, J.D. , WADE, J.C. & MITCHELL, C.D., SARAL, R., LIETMAN, P.S., DURACK, D.T., LEVIN, M.J., SEGRETI, A.C. & BALFOUR, H.H. (1982a). Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host. Am. J. Med., 73 (Suppl. 1A), 229–235.Google Scholar
  40. MINDEL, A. ADLER, M.W., SUTHERLAND, S. & FIDDIAN, A.P. (1982). Intravenous acyclovir treatment for primary genital herpes. Lancet, i, 697–700.Google Scholar
  41. NILSEN, A.E., AASEN, T., HALSOS, A.M., KINGE, B.R., TJOTTA, E.A.L., WIKSTROM, K. & FIDDIAN, A.P. (1982). Efficacy of oral acyclovir in the treatment of the initial and recurrent genital herpes. Lancet, ii, 571–573.Google Scholar
  42. ORENSTEIN, W.A., HEYMANN, D.L., ELLIS, R.J., et al. (1981). Prophylaxis of varicella in high-risk children: dose-response effect of zoster immune globulin. J. Pediatr., 98, 368–373.PubMedCrossRefGoogle Scholar
  43. PAVAN-LANGSTON, D. & BUCHANAN, R.A. (1976). Vidarabine therapy of simple and IDU-complicated herpetic keratitis. Trans. Am. Acad. Ophthalmol. Otolaryngol., 81, OP813–OP825.Google Scholar
  44. PAVAN-LANGSTON, D., LASS, J., HETTINGER, M. & UDELL, I. (1981). Acyclovir and vidarabine in the treatment of ulcerative herpes simplex keratitis. Am. J. Ophthalmol., 92, 829–835.Google Scholar
  45. PAZIN, G.J., ARMSTRONG, J.A., LAM, M.T., TARR, G.C., JANNETTA, P.J. & HO, M. (1979). Prevention of reactivated herpes simplex infection by human leukocyte interferon after operation on the trigeminal root. N. Engl. J. Med., 301, 225–230.Google Scholar
  46. PAZIN, G.J., HO. M., HAVERKOS, H.W., ARMSTRONG, J.A., BREINIG, M.C., WECHSLER, H.L., ARVIN, A., MERIGAN, T.C. & CANTELL, K. (1982). Effects of interferon-alpha on human warts. J. Interferon Res., 2, 235–243.Google Scholar
  47. POLLARD, R.B., EGBERT, P.R., GALLAGHER, J.G. & MERIGAN, T.C. (1980). Cytomegalovirus retinitis in immunosuppressed hosts. I. Natural history and effects of treatment with adenine arabinoside. Ann. intern. Med., 93, 655–664.Google Scholar
  48. POLLARD, R., SMITH, J., NEAL, E., GREGORY, P., MERIGAN, T. & ROBINSON, W. (1978). Effect of vidarabine on chronic hepatitis B infection. JAMA, 239, 1648–1661.Google Scholar
  49. PROBER, C.G., KIRK, L.E. & KEENEY, R.E. (1982). Acyclovir therapy of chicken pox in immunosuppressedGoogle Scholar
  50. children — a collaborative study. J. Pediatr., 101, 622–625.Google Scholar
  51. REICHMAN, R.C., BADGER, G.J., MERTZ, G.J., COREY, L., RICHMAN, D.D., CONNOR, J.D. 10 OTHERS. (1984). Treatment of recurrent genital herpes simplex infections with oral acyclovir. JAMA, 251, 2103–2107.PubMedCrossRefGoogle Scholar
  52. ROSS, A.H. (1962). Modification of chicken pox in family contacts by administration of gamma globulin. N. Engl. J. Med., 267, 369–376.PubMedCrossRefGoogle Scholar
  53. SARAL, R., AMBINDER, R.F., BURNS, W.H., ANGELOPULOS, E.M., GRIFFIN, D.E., BURKE, P.J. & LIETMAN, P.S. (1983). Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. Ann. intern. Med., 99, 773–776.Google Scholar
  54. SARAL, R., BURNS, W.H., LASKIN, O.L., SANTOS, G.W. & LEITMAN, P.S. (1981). Acyclovir prophylaxis of herpes simplex virus infections: a randomized double-blind, controlled trial in bone marrow transplant recipients. N. Engl. J. Med., 305, 63–67.Google Scholar
  55. SCULLARD, G.H., POLLARD, R.B., SMITH, J.L., SACKS, S.L., GREGORY, P.B., ROBINSON, W.S. & MERIGAN, T.C. (1981b). Antiviral treatment of chronic hepatitis B virus infection. I. Changes in viral markers with interferon combined with adenine arabinoside. J. Infect. Dir., 143, 772–783.Google Scholar
  56. SCULLARD, G.H., SMITH, C.I., MERIGAN, T.C., ROBINSON, W.S. & GREGORY, P.B. (1981a). Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B. Gastroenterology, 81, 987–991.Google Scholar
  57. SHONFELD, A., SCHATTNER, A. CRESPI, M., LEVAVI, H., SHOHAM, J., NITKE, S. 5 OTHERS. (1984). Intramuscular human interferon-beta infections in treatment of conylomato acuminata. Lancet, i, 1038–1042.CrossRefGoogle Scholar
  58. SHULMAN, S.T., HUTTO, J.H., AYOUB, E.M., HOWLETT, S.A., SCOTT, B. & McGUIGAN, J.E. (1979). A double blind evaluation of transfer factor therapy of HBsAg positive chronic aggressive hepatitis: preliminary report of efficacy. Cell. Immunol., 43, 352–361.Google Scholar
  59. SMITH, C., KITCHEN, L., SCULLARD, G., ROBINSON, W., GREGORY, P. & MERIGAN, T. (1982). Vidarabine monophosphate and human leukocyte interferon in chronic hepatitis B infection. JAMA, 247, 2261–2265.Google Scholar
  60. STRAUS, S.E., SEIDLIN, M., TAKIFF, H., JACOBS, D., BOWEN, D. & SMITH, H.A. (1984). Oral acyclovir to suppress recurring herpes simplex virus infections in immuno-deficient patients. Ann. intern. Med., 100, 522–524.Google Scholar
  61. SULLIVAN, J.L., BYRON, K.S., BREWSTER, F.E., KARAMOTO, K., SHAW, J.E. & PAGANO, J.S. (1982). Treatment of life-threatening Epstein-Barr virus infection with acyclovir. Am. J. Med., 73 (Suppl. 1A), 262–266.Google Scholar
  62. SUNDMACHER, R., CANTELL, K., MATTES, A. (1984). Combination therapy for dendritic keratitis high titer alpha-interferon and trifluridine. Arch. Ophthalmol., 102, 554–555.PubMedCrossRefGoogle Scholar
  63. SUNDMACHER, R., CANTELL, K., NEUMANN-HAEFELIN, D. (1978). Combination therapy of dendritic keratitis with trifluorothymidine and interferon. Lancet, 2, 687.PubMedCrossRefGoogle Scholar
  64. SUZUKI, S., SAITO, S., WATANABE, S., KOJIMA, H., YOSHIKAWA, A. & ICHIDA, F. (1983). Clinical trial of oral Ara-A on chronic HBV infection. In Abstracts, Fourth US-Japan Hepatitis Research Conference. Google Scholar
  65. TONG, M., NYSTROM, J., REDEKER, A. & MARSHALL, G. (1976). Failure of transfer factor therapy in chronic active type B hepatitis. N. Engl. J. Med., 295, 209–211.Google Scholar
  66. VILELA, M. DE P., SEQUEIRA, W. DE A., DOMINQUES, S.H.S., RODRIGUES, L.D. & RODRIGUES, F.S. (1975). Action of a new anti-viral drug on the Australia antigen in patients with virus hepatitis and in healthy carriers. Revista Brasileira Quimotherapeutica, 4, 451.Google Scholar
  67. WADE, J.C., HINTZ, M., McGUFFIN, R. W., SPRINGMEYER, S.C., CONNOR, J.D. & MEYERS, J.D. (1982b). Treatment of cytomegalovirus pneumonia with high dose acyclovir. Am. J. Med., 73 (Suppl. 1A), 249–256.Google Scholar
  68. WADE, J.C., McGUFFIN, R.W., SPRINGMEYER, S.C., NEWTON, B., SINGER, J.W. & MEYERS, D.J. (1983). Treatment of cytomegaloviral pneumonia with high-dose acyclovir and human leukocyte interferon. J. Infect. Dis., 148, 557–562.Google Scholar
  69. WADE, J.C., NEWTON, B., McLAREN, C., FLUORNOY, N., KENNEY, R.E. & MEYERS, J.D. (1982a). Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation. Ann. intern. Med., 96, 265–269.Google Scholar
  70. WELLER, I.V.D., BASSENDINE, M.F., CRAXI, A., FOWLER, M.J.F., MONJARDINO, J., THOMAS, H.C. & SHERLOCK, S. (1982). Successful treatment of HBs and HBeAg positive chronic liver disease: prolonged inhibition of viral replication by highly soluble adenine arabinoside 5′monophosphate. Gut, 23, 717–723.Google Scholar
  71. WHITLEY, R., HILTY, M., HAYNES, R., BRYSON, Y., CON- NOR, J.D., SOONG, S.J., ALFORD, C.A. (1982). Vidarabine therapy of varicella in immunosuppressed patients. J. Pediatr., 101, 125–131.Google Scholar
  72. WHITLEY, R.J., NAHMIAS, A.J., SOONG, S.J., GALASSON, G.G., FLEMING, C.L., ALFORD, C.A. (1980). Vidarabine therapy of neonatal herpes simplex virus infection. Pediatrics, 66, 495–501.PubMedGoogle Scholar
  73. WHITLEY, R.J., SOONG, S.J., DOLIN, R., GALASSO, G.J., CH’IEN, L.T., ALFORD, C.A., Collaborative Study Group. (1977). Adenine arabinoside therapy of biopsyproved herpes simplex encephalitis. N. Engl. J. Med., 297, 289–294.Google Scholar
  74. WHITLEY, R.J., SOONG, S.J., HIRSCH, M.S., KARCHMER, A.W., DOLIN, R., GALASSO, G.J., DUNNICK, J.K., ALFORD, C.A., NIAID Collaborative Study Group. (1981). Herpes simplex encephalitis. Vidarabine therapy and diagnostic problems. N. Engl. J. Med., 304, 313–318.Google Scholar
  75. WINSTON, D.J., POLLARD, R.B., HO, W.G., GALLAGHER, J.G., RASMUSSEN, L.E., HUANG, S.N. & 4 OTHERS. (1982). Cytomegalovirus immune plasma in bone marrow transplant recipients. Ann. intern. Med., 97, 11–18.Google Scholar
  76. YOUNG, B.J., PA1TERSON, A. & RAVENSCROFF, T. (1982). A randomized double-blind clinical trial of acyclovir (Zovirax) and adenine arabinoside in herpes simplex corneal ulceration. Br. J. Ophthalmol., 66, 361–363.Google Scholar

Copyright information

© Macmillan Publishers Limited 1984

Authors and Affiliations

  • M. Eisenberg
    • 1
  • T. C. Merigan
  1. 1.Division of Infectious Diseases, Department of MedicineStanford UniversityCaliforniaUSA

Personalised recommendations